Three-year results comparing platinum-chromium PROMUS element and cobalt-chromium XIENCE V everolimus-eluting stents in de novo coronary artery narrowing (from the PLATINUM Trial)

Ian T Meredith, Paul S Teirstein, Alain Bouchard, Didier Carrie, Helge Mollmann, Keith G Oldroyd, Jack Hall, Dominic J Allocco, Keith D Dawkins, Gregg W Stone

Research output: Contribution to journalArticleResearchpeer-review

32 Citations (Scopus)


Everolimus-eluting stents have become the most commonly used drug-eluting stents (DES), in part because of data from clinical trials showing significantly reduced rates of revasculization, myocardial infarction (MI), and stent thrombosis with the PROMUS or XIENCE V everolimus-eluting, cobalt-chromium stent compared with early generation paclitaxel-eluting stents.
Original languageEnglish
Pages (from-to)1117-1123
Number of pages7
JournalThe American Journal of Cardiology
Issue number7
Publication statusPublished - 2014
Externally publishedYes

Cite this